同源康医药-B(02410.HK) 公布,获浙江省药品监督管理局颁发药品生产许可证,生产范围甲磺酸艾多替尼片。预期将对公司扩大产能及拓展市场产生长远的积极作用,为后续开展商业化生产奠定基础。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-01-23 16:25。)AASTOCKS新闻
Source Link同源康医药-B(02410.HK) 公布,获浙江省药品监督管理局颁发药品生产许可证,生产范围甲磺酸艾多替尼片。预期将对公司扩大产能及拓展市场产生长远的积极作用,为后续开展商业化生产奠定基础。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-01-23 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.